LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results
| Autor: | Harbeck, N. 1, Nitz, U. 2, Christgen, M. 3, Kuemmel, S. 4, Braun, M. 5, Schumacher, C. 6, Potenberg, J. 7, Tio, J. 8, Aktas, B. 9, Malter, W. 10, Forstbauer, H. 11, von Schumann, R. 12, Just, M. 13, Jóźwiak, K. 14, Hauptmann, M. 14, Kates, R. 15, Gräser, M. 16, Wuerstlein, R. 17, Kreipe, H. 3 |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S1146-S1146 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|